Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
General Internal Medicine
Obesity
Questions discussed in this category
How should clinicians balance the use of finerenone with other heart failure treatments like SGLT2 inhibitors, considering their glycemic benefits?
Butt et al., PMID 39818225
2 Answers available
22911
Papers discussed in this category
European heart journal, 2016-07-14
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
The New England journal of medicine, 2024 Sep 01
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
Circulation, 2024 Sep 28
Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure.
Related Topics in General Internal Medicine
Lung Cancer
Breast Cancer
Head and Neck Cancers
Hematologic Malignancies
Radiation Oncology
Gynecologic Oncology
Palliation
Neuro-Oncology
Gastrointestinal Cancers
Genitourinary Cancers